Ricardo Baptista

Ricardo Baptista currently serves as Chief Technology Officer at SmartCella Holding AB since April 2024 and as an Advisor for Plurify and NorthX Biologics. Additionally, Ricardo is a Steering Committee Member for Industry Best Practices at the International Society for Stem Cell Research since March 2023 and previously held the position of Chief Technology Officer at Alder Therapeutics until March 2024. Prior roles include Director of CMC & Development at Procella Therapeutics AB and Director of Process & Analytical Development at Cellectis. With a strong background in process development, Ricardo worked at the Cell and Gene Therapy Catapult, along with other positions in project management and development at CCRM and the University of Toronto. Educational credentials include a PhD in Biotechnology and Biochemical Engineering from Instituto Superior Técnico and studies in Protein Biophysics at Aalborg University.